参考文献
［1］中华医学会心血管病学分会中国成人肥厚型心肌病诊断与治疗指南编写组，中华心血管病杂志编辑委员会.中国成人肥厚型心肌病诊断与治疗指南［J］.中华心血管病杂志，2017，45（12）：1015-1032.
［2］Maron MS，Olivotto I，Zenovich AG，et al.Hypertrophic Cardiomyopathy Is Predominantly a Disease of Left Ventricular Outflow Tract Obstruction［J］.Circulation，2006，114（21）：2232-2239.
［3］Maron BJ，Shirani J，Poliac LC，et al.Sudden Death in Young Competitive Athletes Clinical，Demographic，and Pathological Profile［sJ］.The Journal of the American Medical Association，1996，276（3）：199-204.
［4］Semsarian C，Ingles J，Maron MS，et al.New perspectives on the prevalence of hypertrophic cardiomyopathy［J］.Journal of the American College of Cardiology，2015，65（12）：1249-1254.
［5］Guidelines for Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy（JCS 2012）— Digest Version［J］.Circ J，2016，80（3）：753-774.
［6］Matsumori A，Furukawa Y，Hasegawa K，et al.Epidemiologic and clinical characteristics of cardiomyopathies in Japan：results from nationwide survey［sJ］.Circ J，2002，66（4）：323-336.
［7］Maron BJ，Spirito P，Roman MJ，et al.Prevalence of hypertrophic cardiomyopathy in a population-based sample of American Indians aged 51 to 77 years（the Strong Heart Study）［J］.Am J Cardiol，2004，93（12）：1510-1514.
［8］Maron BJ，Gardin JM，Flack JM，et al.Prevalence of hypertrophic cardiomyopathy in a general population of young adults.Echocardiographic analysis of 4111 subjects in the CARDIA Study.Coronary Artery Risk Development in（Young）Adult［sJ］.Circulation，1995，92（4）：785-789.
［9］Maron BJ，Olivotto I，Spirito P，et al.Epidemiology of hypertrophic cardiomyopathy-related death：revisited in a large non-referral-based patient population［J］.Circulation，2000，102（8）：858-864.
［10］Zou Y，Song L，Wang Z，et al.Prevalence of idiopathic hypertrophic cardiomyopathy in China：a population-based echocardiographic analysis of 8080 adult［sJ］.Am J Med，2004，116（1）：14-18.
［11］Jain P，Patel PA，Fabbro M.Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction：Expecting the Unexpected［J］.2nd.J Cardiothorac Vasc Anesth，2018，32（1）：467-477.
［12］Elliott PM，Anastasakis A，Borger MA，et al.2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy：the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology（ESC）［J］.Eur Heart J，2014，35（39）：2733-2779.
［13］王福军，罗亚雄.心肌病用药策略［M］.北京：人民军医出版社，2014.
［14］Smith BB，Nickels AS，Sviggum HP.A rare combination of undiagnosed hypertrophic cardiomyopathy revealed by intraoperative anaphylaxis resulting in acute left ventricular outflow obstruction and cardiac arres［tJ］.J Clin Anesth，2016，31：212-214.
［15］Elliott PM，Anastasakis A，Borger MA，et al.2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy［J］.Kardiol Pol，2014，72（11）：1054-1126.
［16］Rapezzi C，Arbustini E，Caforio AL，et al.Diagnostic work-up in cardiomyopathies：bridging the gap between clinical phenotypes and final diagnosis.A position statement from the ESC Working Group on Myocardial and Pericardial Diseases［J］.Eur Heart J，2013，34（19）：1448-1458.
［17］Chen X，Zhao S，Zhao T，et al.Prasad.T-wave inversions related to left ventricular basal hypertrophy and myocardial fibrosis in non-apical hypertrophic cardiomyopathy：a cardiovascular magnetic resonance imaging study［J］.Eur J Radiol，2014，83（2）：297-302.
［18］Vogelsberg H，Mahrholdt H，Deluigi CC，et al.Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis：noninvasive imaging compared to endomyocardial biopsy［J］.J Am Coll Cardiol，2008，51（10）：1022-1030.
［19］Maron BJ，McKenna WJ，Danielson GK，et al.American College of Cardiology /European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy：A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guideline［sJ］.J Am Coll Cardiol，2003，42（9）：1687-1713.
［20］Xuan TM，Zeng Y，Zhu WL.Risk of patients with hypertrophic cardiomyopathy undergoing noncardiac surgery［J］.Chin Med Sci J，2007，22（4）：211-215.
［21］Thompson RC，Liberthson RR，Lowenstein E.Perioperative anesthetic risk of noncardiac surgery in hypertrophic obstructive cardiomyopathy［J］.The Journal of the American Medical Association，1985，254（17）：2419-2421.
［22］Kuroiwa M，Arai M，Ueno T，et al.Perioperative cardiovascular complications in patients with hypertrophic cardiomyopathy［J］.Masui，2003，52（7）：733-739.
［23］Luckner G，Margreiter J，Jochberger S，et al.Systolic anterior motion of the mitral valve with left ventricular outflow tract obstruction：three cases of acute perioperative hypotension in noncardiac surgery［J］.Anesth Analg，2005，100（6）：1594-1598.
［24］Walsh M，Devereaux PJ，Garg AX，et al.Relationship between intraoperative mean arterial pressure and clinical outcomes after noncardiac surgery：toward an empirical definition of hypotension［J］.Anesthesiology，2013，119（3）：507-515.
［25］郭航远.新编心肌病学［M］.杭州：浙江大学出版社，2007.
［26］Hensley N，Dietrich J，Nyhan D，et al.Hypertrophic cardiomyopathy：a review［J］.Anesth Analg，2015，120（3）：554-569.
［27］Yang WI，Shim CY，Kim YJ，et al.Left atrial volume index：a predictor of adverse outcome in patients with hypertrophic cardiomyopathy［J］.J Am Soc Echocardiogr，2009，22（12）：1338-1343.
［28］Gabrielle，Norrish，Natalie，et al.Outcomes following general anaesthesia in children with hypertrophic cardiomyopathy［J］.Archives of Disease in Childhood，2018.
［29］Philipson DJ，Rader F，Siegel RJ.Risk factors for atrial fibrillation in hypertrophic cardiomyopathy［J］.European Journal of Preventive Cardiology，2019.
［30］Fananapazir L，McAreavey D.Hypertrophic cardiomyopathy：evaluation and treatment of patients at high risk for sudden death［J］.Pacing Clin Electrophysiol，1997，20（2 Pt 2）：478-501.
［31］Hreybe H，Zahid M，Sonel A，et al.Saba.Noncardiac surgery and the risk of death and other cardiovascular events in patients with hypertrophic cardiomyopathy［J］.Clin Cardiol，2006，29（2）：65-68.
［32］Chang KH，Sano E，Saitoh Y，et al.Anesthetic management of patients with hypertrophic obstructive cardiomyopathy undergoing non-cardiac surgery［J］.Masui，2004，53（8）：934-942.
［33］Haering JM，Comunale ME，Parker RA，et al.Cardiac risk of noncardiac surgery in patients with asymmetric septal hypertrophy［J］.Anesthesiology，1996，85（2）：254-259.
［34］Dhillon A，Khanna A，Randhawa MS，et al.Perioperative outcomes of patients with hypertrophic cardiomyopathy undergoing non-cardiac surgery［J］.Heart，2016，102（20）：1627-1632.
［35］华伟，张澍，王方正，等.植入型心律转复除颤器抗心动过速起搏治疗室性心动过速疗效评价［J］.中华心律失常学杂志，2005，9（5）：341-343.
［36］Schinkel AF，Vriesendorp PA，Sijbrands EJ，et al.Outcome and complications after implantable cardioverter defibrillator therapy in hypertrophic cardiomyopathy：systematic review and meta-analysi［sJ］.Circ Heart Fail，2012，5（5）：552-559.
［37］Kaski JP，Tome Esteban MT，Lowe M，et al.Outcomes after implantable cardioverter-defibrillator treatment in children with hypertrophic cardiomyopathy［J］.Heart，2007，93（3）：372-374.
［38］Marin F，Gimeno JR，Paya E，et al.The implantable cardioverter-defibrillator and hypertrophic cardiomyopathy.Experience at three centers［J］.Rev Esp Cardiol，2006，59（6）：537-544.
［39］Pryn A，Bryden F，Reeve W，et al.Cardiomyopathy in pregnancy and caesarean section：four case report［sJ］.Int J Obstet Anesth，2007，16（1）：68-73.
［40］付伟东，舒晓燕.肥厚型心肌病的麻醉处理［J］.温州医学院学报，2001，31（2）：110-111.
［41］沈通桃，张国楼.肥厚型心肌病患者非心脏手术的麻醉处理二例报道［J］.临床麻醉学杂志，2001，20（8）：508.
［42］Poliac LC，Barron ME，Maron BJ.Hypertrophic cardiomyopathy［J］.Anesthesiology，2006，104（1）：183-192.
［43］Gregory SH，Fierro MA.The role of intraoperative transesophageal echocardiographic monitoring in a patient with hypertrophic cardiomyopathy undergoing laparoscopic surgery［J］.Journal of Clinical Anethesia，2016，34：124-127.
［44］迟慧，卿恩明，来永强，等.肥厚型梗阻性心肌病患者行左心室流出道疏通术的麻醉管理［J］.心肺血管病杂志，2013，32（3）：337-339.
［45］肖营凯，周成斌，熊卫萍，等.外科治疗肥厚型梗阻性心肌病围手术期处理［J］.中国体外循环杂志，2015，13（4）：229-231.
［46］Bready LL，Noorily SH，Dillman D.Decision making in anesthesiology［M］.4th ed.Mosby Inc.，an imprint of Elsevier Inc，2011.
［47］Stoelting RK，Miller RD.Basics of Anesthesia［M］.5th ed.Elsevier（Singapore）Pte Ltd，2012.